

Loreev XR[®] (lorazepam extended release)

Policy # 00773

Original Effective Date: 03/14/2022

Current Effective Date: 03/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider Loreev XR^{®†} (lorazepam extended release) to be **eligible for coverage**** when the patient selection criteria are met.

Patient Selection Criteria

Coverage eligibility for Loreev XR (lorazepam extended release) will be considered when the following criteria are met:

- Patient is greater than or equal to 18 years of age; AND
- Patient is currently taking lorazepam immediate release tablets consistently three times daily; AND
- Patient has been on a stable dose of lorazepam for at least 6 weeks; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*
- There is clinical evidence or patient history that suggests the continued use of the generic immediate release lorazepam tablets will be ineffective or cause an adverse reaction to the patient.
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Loreev XR (lorazepam extended release) when the patient has not been on a stable dose of lorazepam for at least 6 weeks or there is an absence of clinical evidence or patient history that suggests the continued use of the generic immediate release lorazepam tablets will be ineffective or cause an adverse reaction to the patient to be **not medically necessary.****

Loreev XR® (lorazepam extended release)

Policy # 00773

Original Effective Date: 03/14/2022

Current Effective Date: 03/01/2026

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Loreev XR (lorazepam extended release) when patient selection criteria are not met (except those denoted above as **not medically necessary****) to be **investigational**.*

Background/Overview

Loreev XR is an extended release formulation of lorazepam that is indicated specifically for patients who are receiving stable, evenly divided, three times daily dosing with immediate release lorazepam tablets. It is available in 1 mg, 2 mg, and 3 mg capsules that should be administered once daily, in the morning, with or without food. The dose should be equal to the patient's previous total daily dose of lorazepam tablets and should be started the morning after the last dose of lorazepam tablets. Capsules may be swallowed whole or opened and the entire contents sprinkled onto applesauce.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Loreev XR was approved in August, 2021, for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The intent of this policy is to ensure that this medication is being used for its FDA approved indication. Loreev XR was approved for use in adults based on safety studies done with lorazepam immediate release tablets and is only indicated in patients who have been stabilized on lorazepam tablets. The patient selection criteria presented in this policy take into consideration whether the patient has been stabilized on the generic lorazepam tablets as well as whether there is a clinical reason that the patient cannot continue to take the generic lorazepam tablets. In the absence of the above mentioned caveats, there is no advantage to using brand name Loreev XR over the available generic lorazepam tablets.

References

1. Loreev XR [package insert]. Almatica Pharma LLC. Morristown, NJ. Updated August 2021.

Loreev XR® (lorazepam extended release)

Policy # 00773

Original Effective Date: 03/14/2022

Current Effective Date: 03/01/2026

Policy History

Original Effective Date: 03/14/2022

Current Effective Date: 03/01/2026

02/03/2022 Medical Policy Committee review

02/09/2022 Medical Policy Implementation Committee approval. New policy.

02/02/2023 Medical Policy Committee review

02/08/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

02/01/2024 Medical Policy Committee review

02/14/2024 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

02/06/2025 Medical Policy Committee review

02/12/2025 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

02/05/2026 Medical Policy Committee review

02/11/2026 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 02/2027

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;

Loreev XR® (lorazepam extended release)

Policy # 00773

Original Effective Date: 03/14/2022

Current Effective Date: 03/01/2026

- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan’s pharmacy benefit.